SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

2395・Prime Market・Services

2395・Prime Market・Services

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.2395

Reference Indicators

Market Cap

541¥100M

P/E (Forecast)

—

P/B

1.3x

Dividend Yield (Forecast)

3.85%

ROE

11.0%

EV/EBITDA

12.5x

Financial Summary

Unit: ¥M

Item	2022Mar 2022	2023Mar 2023	2024Mar 2024	2025Mar 2025	2026Mar 2026
Net Sales	17,748	25,090	26,450	32,413	32,524
Cost of Sales	8,061	12,044	12,167	15,452	16,286
Gross Profit	9,687	13,046	14,282	16,960	16,238
SG&A Expenses	5,491	7,801	10,120	13,975	13,584
Operating Income	4,195	5,245	4,162	2,985	2,653
Non-operating Income	3,011	4,241	3,254	3,845	3,484
Non-operating Expenses	129	292	401	380	305
Ordinary Income	7,078	9,194	7,015	6,450	5,833
Extraordinary Income	1,419	45	86	43	875
Extraordinary Losses	314	1,480	128	480	461
Pre-tax Income	8,183	7,759	6,974	6,013	6,247
Income Taxes	1,016	1,708	1,456	1,148	1,713
Net Income	7,127	6,060	5,531	4,924	4,566
EBITDA	5,373	6,845	6,030	5,596	6,085
Gross Margin	54.6%	52.0%	54.0%	52.3%	49.9%
Operating Margin	23.6%	20.9%	15.7%	9.2%	8.2%
ROA	18.1%	10.6%	7.2%	5.3%	4.3%
ROE	40.4%	26.5%	18.3%	13.3%	11.0%

Segment Performance

Unit: ¥M

2026

Segment	Net Sales	Operating Income	Operating Margin
ＣＲＯ事業	31,204	6,909	22.1%
トランスレーショナルリサーチ事業	105	-4,028	-3836.2%
メディポリス事業	717	-65	-9.1%
米国不動産事業	184	-1	-0.5%
その他	313	13	4.2%

Disclaimer